Skip to main content
Canada OKs Puma Bio's neratinib for early-stage breast cancer
7/17/2019

Health Canada has approved Puma Biotechnology's Nerlynx, or neratinib, as an extended ancillary treatment for women with early-stage breast cancer who have completed prior adjuvant therapy with Roche's Herceptin, or trastuzumab. Knight Therapeutics, Puma Bio's licensee, will handle the product's commercialization.

Full Story: